![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessImpact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma
Treatment duration with checkpoint inhibitors must be optimized to prevent unjustified toxicity, but evidence for the management of cutaneous squamous cell carcinoma is lacking. A retrospective study was perfo...
-
Article
Open AccessUpregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin
BRAF-mutant melanoma patients benefit from the combinatorial treatments with BRAF and MEK inhibitors. However, acquired drug resistance strongly limits the efficacy of these targeted therapies in time. Recentl...
-
Article
Open AccessMelanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps
Polymorphonuclear neutrophils (PMNs) are the main effector cells in the inflammatory response. The significance of PMN infiltration in the tumor microenvironment remains unclear. Metastatic melanoma is the mos...
-
Article
Open AccessThe clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic
COVID-19 pandemic following the outbreak in China and Western Europe, where it finally lost the momentum, is now devastating North and South America. It has not been identified the reason and the molecular mec...
-
Article
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
Engineered cytokine products represent promising agents for the treatment of immunogenic tumors, such as malignant melanoma, in addition to immune checkpoint inhibitors. Here we describe the results of a contr...
-
Article
Open AccessGermline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study
Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant melanoma (CMM). They are often sporadic harbouring several somatic mutations, but also familial cases harbouring a CDKN2A germl...
-
Chapter
Melanoma
Melanoma is a malignant tumor that arises from melanocytic cells and primarily involves the skin. Early diagnosis is fundamental for surgical treatment of localized disease. A conservative surgical excision ap...
-
Article
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We investigated the role of soluble CTLA-4 (s...
-
Article
Open AccessTargeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells
Accumulating evidence demonstrates that the Urokinase Receptor (uPAR) regulates tumor cell migration through its assembly in composite regulatory units with transmembrane receptors, and uPAR88–92 is the minimal s...
-
Article
Open AccessEfficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
Elderly patients with metastatic melanoma have different disease characteristics and a poorer prognosis than younger patients. Data from clinical trials and expanded access programmes (EAPs) suggest ipilimumab...
-
Article
Open AccessLong-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% of patients relapsing within 5 years. For lesions refractory to elective treatments, electroche...
-
Article
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012
-
Article
Open AccessClinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was th...
-
Chapter
Targeting Tumor Angiogenesis
Four decades after the seminal work of Judah Folkman, in 1971, cancer therapies based on the suppression of neo-angiogenesis (Folkman, N Engl J Med 285:1182–1186, 1971) are becoming a reality (Verheul et al., ...
-
Chapter
Therapeutic Targeting of the Bone Pre-metastatic Niche
Most of relevant strategies designed for therapeutic targeting the highly lethal, bone-metastasizing and AR-resistant prostate cancers, have been reported and discussed elsewhere in this book. In this chapter,...
-
Article
Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells
Background: CXCR4, the chemokine receptor for CXCL12, has recently been involved in the metastatic process of several neoplasms. Materials and methods: The expression of CXCR4 was evaluated by immunohistochemistr...
-
Article
Prospective clinical trials of biotherapies in solid tumors: a 5-year survey
Purpose: To review the content and quality of prospective clinical trials of biotherapies in solid tumors. Methods: Data were collected from the literature between 1990 and 2002 on general study characteristic...